GlassScriptPhysician profile
Ananth K Prasad
NPI 1023089703
$7,008.73
in general payments reported to CMS, 2019-2025
34 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $669 · 2021: $834 · 2022: $399 · 2023: $1,270 · 2024: $1,578 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,063 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,062.71 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,335.33 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,189.24 | 2019-2025 | |
| Boston Scientific Corporation | $635.34 | 2020-2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $600.76 | 2019-2024 | Xact |
| Merck Sharp & Dohme LLC | $470.61 | 2021-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $262.19 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Celonova Biosciences, INC. | $255.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $249.31 | 2021-2025 | Farxiga |
| Amgen INC. | $229.03 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $218.04 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $176.74 | 2020-2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $142.09 | 2022-2023 | Evkeeza, Praluent |
| E.R. Squibb & Sons, L.L.C. | $132.19 | 2020-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $129.42 | 2024 | Symplicity G3 |
| Bard Peripheral Vascular, INC. | $101.46 | 2024 | Lutonix Drug Coated Balloon |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $92.99 | 2021 | |
| Scpharmaceuticals INC. | $87.31 | 2024-2025 | |
| Cvrx, INC. | $86.83 | 2024-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.90 | 2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $73.50 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $71.84 | 2019-2022 | |
| Abiomed | $60.24 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $41.73 | 2024 | |
| Amarin Pharma, INC. | $41.18 | 2022-2023 | |
| Acist Medical Systems, INC. | $35.79 | 2023 | |
| Impulse Dynamics (USA) INC. | $34.96 | 2023 | Optimizer |
| Glaxosmithkline, LLC. | $34.18 | 2025 | Arexvy, Shingrix |
| Medicomp INC | $29.19 | 2025 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals, LTD. | $28.76 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $26.89 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $17.74 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.00 | 2019 | |
| Althera Pharmaceuticals LLC | $13.73 | 2021 | |
| Preventice Services, LLC | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananth Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.